

# BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

<https://doi.org/10.1038/s41586-021-03693-y>

Received: 19 May 2021

Accepted: 4 June 2021

Published online: 10 June 2021

 Check for updates

Jianying Liu<sup>1,2,9</sup>, Yang Liu<sup>3,9</sup>, Hongjie Xia<sup>3</sup>, Jing Zou<sup>3</sup>, Scott C. Weaver<sup>1,2,4,5,6</sup>, Kena A. Swanson<sup>7</sup>, Hui Cai<sup>7</sup>, Mark Cutler<sup>7</sup>, David Cooper<sup>7</sup>, Alexander Muik<sup>8</sup>, Kathrin U. Jansen<sup>7</sup>, Ugur Sahin<sup>8</sup>, Xuping Xie<sup>3</sup>, Philip R. Dormitzer<sup>7</sup> & Pei-Yong Shi<sup>2,3,4,5,6</sup>

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents<sup>1–5</sup>. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses—particularly the B.1.617.1 variant—seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.


Since its emergence in late 2019, SARS-CoV-2 has caused more than 174 million infections and more than 3.7 million deaths resulting from COVID-19 worldwide (as of 9 June 2021; <https://coronavirus.jhu.edu/>). Although coronaviruses have a proofreading mechanism to maintain their long genomic RNAs<sup>6</sup>, mutations continuously emerge in circulating viruses. Because the viral spike protein (S) binds to angiotensin-converting enzyme 2 (ACE2), the cellular receptor for virus attachment, and mediates membrane fusion during viral entry, mutations in the spike protein can alter SARS-CoV-2 transmission, tissue tropism, and disease outcome<sup>7</sup>. Indeed, the first prevalent spike mutation, D614G, promotes spike binding to ACE2, leading to enhanced transmission of SARS-CoV-2<sup>3,8–11</sup>. Subsequently, another spike mutation, N501Y, emerged convergently in several variants that were first identified in different locations, including the UK (lineage B.1.1.7), Brazil (lineage P.1), and South Africa (lineage B.1.351)<sup>2</sup>. The N501Y mutation also increases the affinity of the spike for ACE2 and increases viral transmission<sup>12,13</sup>. Some mutations in the spike, such as E484K, contribute to evasion of antibody neutralization. The E484K mutation has emerged independently in many variants, such as P.1, B.1.351, B.1.526 (first identified in New York), B.1.525 (first identified in Nigeria), and P3 (first identified in the Philippines)<sup>1,2,14</sup>. Thus, as the COVID-19 pandemic continues, it is essential to closely monitor the effects of new mutations or combinations of mutations on viral transmission, pathogenesis, and vaccine and therapeutic efficacies.

BNT162b2, an mRNA vaccine that expresses the full prefusion spike glycoprotein of SARS-CoV-2, is 95% effective against COVID-19<sup>15</sup>. The US Food and Drug Administration has authorized BNT162b2 for

vaccination of individuals 12 years of age and older under emergency use provisions. Although the sequence of the mRNA in BNT162b2 is based on the original SARS-CoV-2 isolate<sup>16</sup>, it has previously been shown that sera from individuals immunized with BNT162b2 retained neutralizing activity against all tested variants, including the B.1.1.7, P.1, B.1.351, B.1.429, B.1.526, and B.1.1.7+E484K lineages<sup>1,2,4,5,17</sup>. Since then, a massive second wave of COVID-19 in India has been associated with the expansion of variant B.1.617.1 to 32 countries, B.1.617.2 to 49 countries, and B.1.618 to 6 countries (as of 31 May 2021; [https://cov-lineages.org/lineages/lineage\\_B.1.618.html](https://cov-lineages.org/lineages/lineage_B.1.618.html)). The B.1.617.2 variant has shown evidence of particularly high transmissibility in the UK<sup>18</sup>. In addition, variant B.1.525, which was initially detected in Nigeria, has spread to 49 countries. All of these variants are currently circulating in the USA. The World Health Organization has designated the B.1.617 lineage as a variant of concern and B.1.525 as a variant of interest<sup>18</sup>. This study analyses BNT162b2-elicited neutralization against these newly identified variants.

To examine the effects of the variants' mutations on neutralization, we used a reverse genetic system to swap the complete spike gene from different variants into an early SARS-CoV-2 isolate<sup>19</sup> (USA-WA1/2020, defined as wild-type) (Extended Data Fig. 1a). We prepared five chimeric viruses with different spike proteins, as follows: (1) B.1.525-spike (with Q52R, A67V, H69/Y70 deletion ( $\Delta$ 69/70), Y145 deletion ( $\Delta$ 145), E484K, D614G, Q677H, and F888L from the B.1.525 variant<sup>18</sup>); (2) B.1.617.1-spike (with G142D, E154K, L452R, E484Q, D614G, P618R, Q1071H, H1101D, and a synonymous mutation at D111 (nucleotide T21895C) from the B.1.617.1 variant); (3) B.1.617.2-spike (with T19R, G142D, L452R, T478K, D614G, P681R,

<sup>1</sup>Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. <sup>2</sup>Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. <sup>3</sup>Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. <sup>4</sup>Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. <sup>5</sup>Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. <sup>6</sup>Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. <sup>7</sup>Pfizer Vaccine Research and Development, Pearl River, NY, USA. <sup>8</sup>BioNTech, Mainz, Germany. <sup>9</sup>These authors contributed equally: Jianying Liu, Yang Liu. ✉e-mail: [ugur.sahin@biontech.de](mailto:ugur.sahin@biontech.de); [xuxie@utmb.edu](mailto:xuxie@utmb.edu); [philip.dormitzer@pfizer.com](mailto:philip.dormitzer@pfizer.com); [peshi@utmb.edu](mailto:peshi@utmb.edu)



**Fig. 1 | Neutralization of USA-WA1/2020 and variant SARS-CoV-2 viruses by BNT162b2-induced immune sera.** The PRNT<sub>50</sub> results for USA-WA1/2020 and variant viruses are plotted. Individual PRNT<sub>50</sub> values are presented in Extended Data Table 1. Each data point represents the geometric mean PRNT<sub>50</sub> against the indicated virus obtained with a serum sample collected two weeks (circles) or four weeks (triangles) after the second dose of vaccine. PRNT<sub>50</sub> values were determined in duplicate assays, and the geometric means were calculated ( $n=20$ , pooled from two independent experiments). The heights of bars and the numbers over the bars indicate geometric mean titres; error bars show 95% confidence intervals. LOD, limit of detection at 1:40. Statistical significance (two-tailed Wilcoxon matched-pairs signed-rank test) of the difference between geometric mean titres for USA-WA1/2020 and each variant:  $P=0.002$  for B.1.525-spike,  $P<0.0001$  for B.1.617.1-spike,  $P=0.001$  for B.1.617.2-spike,  $P=0.004$  for B.1.617.2-v2-spike,  $P=0.001$  for B.1.618-spike.

and D950N from an early B.1.617.2 variant (GISAID (<https://www.gisaid.org/>) accession number EPI\_ISL\_1663247); (4) B.1.617.2-v2-spike (with the mutations in B.1.617.2-spike plus an additional E156G substitution and F157–R158 deletion ( $\Delta 157-158$ ) found in currently circulating B.1.617.2 isolates<sup>18</sup>); and (5) B.1.618-spike (with H49Y, Y145–H146 deletion ( $\Delta 145-146$ ), E484K, and D614G from the B.1.618 variant<sup>20</sup>). All mutant viruses yielded infectious titres of more than  $10^7$  plaque-forming units (PFUs) per millilitre. The B.1.617.1-spike virus formed smaller plaques than other viruses on Vero E6 cells (Extended Data Fig. 1b). All viruses were quantified for their viral RNA genome-to-PFU ratios (a parameter that indicates virus infectivity). None of the variant spikes significantly altered the viral RNA-to-PFU ratio (Extended Data Fig. 1c), suggesting that the viruses had similar specific infectivities. The complete spikes of all viral stocks were sequenced to ensure that they contained no undesired mutations.

To compare the susceptibility of different variants to neutralization, we performed 50% plaque reduction neutralization (PRNT<sub>50</sub>) testing using a panel of 20 sera collected from volunteers who were immunized with BNT162b2 in a pivotal clinical trial<sup>15,21</sup>. The serum specimens were drawn two or four weeks after the second of two immunizations with 30  $\mu$ g of BNT162b2, which were spaced three weeks apart (Extended Data Fig. 2). Each serum was tested simultaneously for its PRNT<sub>50</sub> against the wild-type and mutant viruses (Extended Data Table 1). All the sera neutralized the wild-type and all mutant viruses with titres of 1:40 or higher (Fig. 1). The geometric mean neutralizing titres against the wild-type, B.1.525-spike, B.1.617.1-spike, B.1.617.2-spike, B.1.617.2-v2-spike, and B.1.618-spike viruses were 502, 320, 157, 355, 343, and 331, respectively (Fig. 1). The results indicate that neutralization of all variants, except the B.1.617.1 variant, was only modestly reduced relative to neutralization of the wild-type virus. Although neutralization of B.1.617.1 was reduced more strongly, BNT162b2 immune sera efficiently neutralized the B.1.617.1 virus and all of the other viruses.

In response to the global pandemic of COVID-19, the scientific community has increased surveillance to identify mutations in circulating SARS-CoV-2 strains that might increase infectivity, enhance pathogenicity, or alter coverage by therapeutic agents or vaccines. Such information is essential to guide public policy and the development of countermeasures. As part of ongoing diligence on coverage

of variants by the BNT162b2 vaccine, we have engineered variant spike genes into the backbone of the USA-WA1/2020 isolate, and, using the gold standard PRNT<sub>50</sub> assay, tested neutralization of the resulting viruses by a panel of BNT162b2-immunized human sera drawn two or four weeks after the second of two doses of BNT162b2 given three weeks apart<sup>4,5</sup>. Among all tested viruses, those with spike proteins from B.1.351<sup>4</sup> and B.1.617.1 (this study) exhibited the greatest reduction in neutralization by the sera, with PRNT<sub>50</sub> values 0.36 times and 0.31 times, respectively, that of USA-WA1/2020. Similarly, a recent study found that BNT162b2-induced immune sera neutralized a clinical B.1.617.1 isolate with 0.14 times the neutralization titre of the sera against the wild-type virus<sup>22</sup>. Other studies have found that BNT162b2-induced immune sera have 0.25 to 0.35 times the inhibitory titre against a pseudovirus with a B.1.617.1 spike compared to that against wild-type spike pseudovirus<sup>23</sup>, and that BNT162b2-induced immune sera inhibit a pseudovirus with a B.1.618 spike with 0.37 times the serum inhibition titre against a wild-type spike pseudovirus<sup>20</sup>. Our results showed that among the four tested variants that were first identified in India, B.1.617.1 was the least neutralized, probably owing to the presence of both L452R and E484Q substitutions at the receptor binding site (potentially under positive selection for resistance to neutralization by antibodies)<sup>14,24</sup>. Nevertheless, all variants were still neutralized by all tested sera at titres of at least 40. The reduction in neutralization could be a combined effect of mutation-mediated escape from antibody binding and mutation-altered spike function.

A recent real-world study in participants who had received two doses of BNT162b2 demonstrated an effectiveness of 75% against any documented infection and 100% against documented severe, critical, or fatal disease caused by the variant B.1.351<sup>25</sup>, which showed a similar reduction in neutralization titres to B.1.617.1. Consistent with the modest reduction in neutralization of the B.1.617.2 variants by BNT162b2-elicited sera reported here, a test-negative case–control study conducted in the UK found that the real-world effectiveness of two doses of BNT162b2 against B.1.617.2 virus was reduced only modestly to 87.9%, compared with 93.4% effectiveness against B.1.1.7 lineage virus<sup>26</sup>. Thus, reductions in neutralization such as those observed here have not been demonstrated to result in loss of vaccine efficacy against disease. BNT162b2 elicits not only neutralizing antibodies, but also spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells and non-neutralizing antibody-dependent cytotoxicity, which can also serve as immune effectors<sup>27,28</sup>. Because neutralization titres do not measure all potentially protective vaccine responses, they cannot substitute for studies of vaccine efficacy and the real-world effectiveness of COVID-19 vaccines against variants.

A limitation of the current study is the potential for mutations to alter neutralization by affecting spike function rather than antigenicity, even though the variant viruses exhibited similar infectious titres and specific infectivities to the original USA-WA1/2020 isolate. In addition, we examined the effect of mutations only in the spike glycoproteins. Mutations outside the spike gene could also affect viral replication and host immune response. We also did not examine the durability of neutralization titres against the variant viruses.

New variants will continue to emerge as the pandemic persists. To date, there is no evidence that virus variants have escaped BNT162b2-mediated protection from COVID-19. Therefore, increasing the proportion of the population immunized with current safe and effective authorized vaccines remains a key strategy to minimize the emergence of new variants and end the COVID-19 pandemic.

## Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-021-03693-y>.

1. Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat. Med.* **27**, 717–726 (2021).
2. Xie, X. et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. *Nat. Med.* **27**, 620–621 (2021).
3. Plante, J. A. et al. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature* **592**, 116–121 (2021).
4. Liu, Y. et al. Neutralizing activity of BNT162b2-elicited serum. *N. Engl. J. Med.* **384**, 1466–1468 (2021).
5. Liu, Y. et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMc2106083> (2021).
6. Smith, E. C., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. *PLoS Pathog.* **9**, e1003565 (2013).
7. Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020).
8. Korber, B. et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **182**, 812–827.e19 (2020).
9. Yurkovetskiy, L. et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. *Cell* **183**, 739–751.e8 (2020).
10. Hou, Y. J. et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* **370**, 1464–1468 (2020).
11. Zhou, B. et al. SARS-CoV-2 spike D614G change enhances replication and transmission. *Nature* **592**, 122–127 (2021).
12. Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. *J. Virol.* **94**, e00127-20 (2020).
13. Liu, Y. et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. Preprint at <https://doi.org/10.1101/2021.03.08.434499> (2021).
14. Ku, Z. et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. *Nat. Commun.* **12**, 469 (2021).
15. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).
16. Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature* **592**, 283–289 (2021).
17. Zou, J. et al. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. *NPJ Vaccines* **6**, 44 (2021).
18. World Health Organization *Coronavirus Disease (COVID-19): Weekly Epidemiological Update (11 May 2021)* <https://reliefweb.int/report/world/coronavirus-disease-covid-19-weekly-epidemiological-update-11-may-2021> (OCHA, 2021).
19. Xie, X. et al. An infectious cDNA clone of SARS-CoV-2. *Cell Host Microbe* **27**, 841–848.e3 (2020).
20. Tada, T. et al. The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies. Preprint at <https://doi.org/10.1101/2021.05.14.444076> (2021).
21. Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. *N. Engl. J. Med.* **383**, 2439–2450 (2020).
22. Edara, V. V. et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. Preprint at <https://doi.org/10.1101/2021.05.09.443299> (2021).
23. Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab and evades antibodies induced by infection and vaccination. Preprint at <https://doi.org/10.1101/2021.05.04.442663> (2021).
24. Tchesnokova, V. et al. Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. Preprint at <https://doi.org/10.1101/2021.02.22.432189> (2021).
25. Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMc2104974> (2021).
26. Bernal, J. L. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. Preprint at <https://doi.org/10.1101/2021.05.22.21257658> (2021).
27. Tauzin, A. et al. A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responses. Preprint at <https://doi.org/10.1101/2021.03.18.435972> (2021).
28. Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. *Nature* <https://doi.org/10.1038/s41586-021-03653-6> (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2021

## Methods

### Cells

African green monkey kidney epithelial Vero E6 cells (ATCC) were grown in Dulbecco's modified Eagle's medium (DMEM; Gibco/Thermo Fisher) with 10% fetal bovine serum (FBS; HyClone Laboratories) and 1% antibiotic/streptomycin (Gibco). The cell line was authenticated through STR profiling by ATCC and tested negative for mycoplasma.

### Construction of SARS-CoV-2s with variant spikes

All mutations from individual variant spike genes were engineered into an infectious cDNA clone of isolate USA-WA1/2020<sup>19</sup>. The spike mutations were introduced using a standard PCR-based mutagenesis method. A detailed protocol for construction of recombinant SARS-CoV-2 has previously been reported<sup>29</sup>. In brief, the full-length cDNAs of viral genome containing the variant spike mutations were assembled by T4 ligase-mediated in vitro ligation. The resulting genome-length cDNAs were used as templates to in vitro transcribe full-length viral RNAs. The in vitro transcribed full-length viral RNAs were electroporated into Vero E6 cells. When electroporated cells developed cytopathic effects (due to recombinant virus production and replication) on day 2 after electroporation, the original viral stocks (P0) were collected from the culture medium. The P0 viruses were amplified for another round on Vero E6 cells to produce the P1 stocks of viruses. The infectious titres of P1 viruses were measured by plaque assay on Vero E6 cells as previously described<sup>19</sup>. The complete sequences of spike genes from the P1 viruses were verified by Sanger sequencing to ensure that there were no undesired mutations. The P1 viruses were used for subsequent neutralization testing.

### Characterization of wild-type and mutant recombinant SARS-CoV-2s

To determine the specific infectivity of each virus, we quantified the P1 stocks for their genomic RNA content and PFUs by quantitative PCR with reverse transcription (RT-qPCR) and plaque assay on Vero E6 cells, respectively. The protocols for RT-qPCR and plaque assay have previously been reported<sup>3</sup>. Genomic viral RNA-to-PFU ratios (genomes/PFU) were calculated to indicate the specific infectivity of each virus preparation.

### BTN162b2 vaccine-immunized human sera

A panel of 20 serum specimens was collected from 15 BTN162b2-immunized participants in a clinical trial<sup>15,21</sup>. The sera were collected two or four weeks after the second of two doses of 30 µg BNT162b2 mRNA, spaced three weeks apart (Extended Data Fig. 2). Five of the 20 participants provided sera at both two and four weeks after the second dose of vaccine, as detailed in the footnote to Extended Data Table 1.

### Plaque-reduction neutralization assay

A PRNT<sub>50</sub> assay, which represents the gold standard neutralization assay, was performed to quantify serum-mediated virus suppression.

Individual sera were twofold serially diluted in culture medium with a starting dilution of 1:40. The diluted sera were mixed with 100 PFU of wild-type USA-WA1/2020 or variant mutant SARS-CoV-2. After 1 h incubation at 37 °C, the serum and virus mixtures were inoculated onto 6-well plates with a monolayer of Vero E6 cells pre-seeded the previous day. The minimal serum dilution that suppressed more than 50% of viral plaques is defined as PRNT<sub>50</sub>. A detailed PRNT<sub>50</sub> protocol has previously been reported<sup>21,30</sup>.

### Statistical analysis

Statistical analyses were performed by Graphpad Prism 9 for all experiments as detailed in the figure legends. No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

### Data availability

Source data for generating the main figures are available in the online version of the paper. Any other data are available upon request.

29. Xie, X. et al. Engineering SARS-CoV-2 using a reverse genetic system. *Nat. Protocols* **16**, 1761–1784 (2021).
30. Muruato, A. E. et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. *Nat. Commun.* **11**, 4059 (2020).

**Acknowledgements** The study was supported by Pfizer and BioNTech. We thank the participants in Pfizer–BioNTech clinical trial C4591001, from whom the post-immunization human sera were obtained. We also thank our colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine candidate.

**Author contributions** Conceptualization: K.U.J., U.S., X.X., K.A.S., A.M., P.R.D., P.-Y.S.; methodology: J.L., Y.L., H.X., J.Z., S.C.W., K.A.S., H.C., A.M., K.U.J., U.S., X.X., P.R.D., P.-Y.S.; investigation: J.L., Y.L., H.X., J.Z., S.C.W., K.A.S., H.C., M.C., D.C., K.U.J., U.S., X.X., P.R.D., P.-Y.S.; data curation: J.L., Y.L., M.C., D.C., X.X., P.-Y.S.; writing, original draft: J.L., Y.L., U.S., X.X., P.R.D., P.-Y.S.; writing, review and editing: S.C.W., K.A.S., A.M., K.U.J., U.S., X.X., P.R.D., P.-Y.S.; supervision: K.U.J., U.S., X.X., P.R.D., P.-Y.S.; funding acquisition: K.U.J., U.S., P.R.D., P.-Y.S.

**Competing interests** X.X. and P.-Y.S. have filed a patent on the reverse genetic system of SARS-CoV-2. K.A.S., H.C., M.C., D.C., K.U.J., and P.R.D. are employees of Pfizer and may hold stock options. A.M. and U.S. are employees of BioNTech and may hold stock options. Y.L., H.X., J.Z., X.X. and P.-Y.S. received compensation from Pfizer to perform the project.


### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41586-021-03693-y>.

**Correspondence and requests for materials** should be addressed to U.S., X.X., P.R.D. or P.-Y.S.

**Peer review information** Nature thanks the anonymous reviewers for their contribution to the peer review of this work.

**Reprints and permissions information** is available at <http://www.nature.com/reprints>.




Extended Data Fig. 1 | See next page for caption.

# Article

## Extended Data Fig. 1 | Construction and characterization of SARS-CoV-2s with variant spikes. **a**, Diagram of engineered variant spike mutations.

Mutations from variant spikes were engineered into isolate USA-WA1/2020. Mutations and deletions are indicated in red and by dotted lines, respectively. Nucleotide and amino acid positions are also indicated. Different regions of SARS-CoV-2 genome are indicated: L (leader sequence), ORF (open reading frame), RBD (receptor binding domain), S (spike glycoprotein), S1 (N-terminal furin cleavage fragment of S), S2 (C-terminal furin cleavage fragment of S), E (envelope protein), M (membrane protein), N (nucleoprotein), and UTR (untranslated region). **b**, Plaque morphologies of recombinant SARS-CoV-2s. Plaque assays were performed on Vero E6 cells in six-well plates. **c**, Comparison

of viral genomic RNA-to-PFU ratios ( $\log_{10}[\text{RNA}/\text{PFU}]$ ) of recombinant SARS-CoV-2s. The genomic RNA and PFU of individual virus stocks were measured by RT-qPCR and plaque assay, respectively. The RNA/PFU ratios were calculated to determine specific infectivities. Dots represent individual biological replicates from four aliquots of viruses ( $n = 4$ , one experiment). Bars and error bars show means with 95% confidence intervals. A non-parametric two-tailed Mann-Whitney test was used to determine the significance of differences between USA-WA1/2020 and variant viruses. *P* values were adjusted using the Bonferroni correction to account for multiple comparisons. Differences were considered significant if  $P < 0.05$ ; n.s., no statistical difference.



**Extended Data Fig. 2 | BNT162b2 immunization scheme and serum collection.** Twenty human sera were obtained from 15 trial participants, 2 weeks (circles) or 4 weeks (triangles) after the second dose of BNT162b2

vaccine. Five of the 15 participants provided sera at both 2 and 4 weeks after the second dose of vaccine.

# Article

**Extended Data Table 1 | PRNT<sub>50</sub> values of sera from BNT162b2-immunized trial participants against USA-WA1/2020 and variant SARS-CoV-2 viruses**

ID <sup>‡</sup>	Serum*			PRNT <sub>50</sub> <sup>†</sup>										
	Age (years)	Sex	Week	USA-WA1/2020			B.1.525-	B.1.617.1-spike			B.1.617.2-	B.1.617.2-	B.1.618-	
				Exp1	Exp2	GMT	spike	Exp1	Exp2	GMT	spike	v2-spike	spike	
1	68	F	2	640	640	640	640	320	320	320	320	320	320	320
2	67	M	2	160	160	160	80	40	40	40	80	80	80	80
3	68	F	2	1280	1280	1280	640	320	320	320	640	640	1280	1280
4	66	F	2	320	320	320	320	80	160	113	320	160	160	160
5	30	M	2	320	640	453	160	80	160	113	320	320	320	160
6	23	F	2	320	320	320	320	80	160	113	160	160	320	320
7	54	M	2	640	640	640	640	160	320	226	640	640	640	640
8	69	F	2	320	320	320	160	80	160	113	320	320	320	320
9	65	M	2	640	640	640	640	160	320	226	640	640	640	640
10	38	F	2	640	640	640	640	320	320	320	640	640	640	640
11	44	F	2	320	640	453	640	160	320	226	320	640	320	320
12	52	F	2	640	640	640	320	160	320	226	320	640	320	320
13	28	M	2	1280	1280	1280	320	160	320	226	640	640	320	320
14	69	F	4	320	320	320	160	80	160	113	320	320	320	320
15	68	F	4	320	320	320	160	80	160	113	320	320	320	320
16	26	F	4	320	320	320	320	80	160	113	320	320	320	320
17	54	M	4	640	640	640	320	160	160	160	640	320	320	320
18	35	F	4	640	640	640	320	160	160	160	320	320	320	320
19	44	F	4	640	640	640	320	80	160	113	320	320	320	320
20	52	F	4	640	640	640	320	160	160	160	320	160	320	320
	GMT <sup>§</sup>			485	520	502	320	126	197	157	355	343	331	331
	95% CI <sup>  </sup>			380-619	410-659	397-636	242-423	96-163	155-245	124-199	278-452	260-452	253-433	253-433

\*Pairs of sera were obtained from five of the twenty participants at both 2 and 4 weeks after the second dose of vaccine. The paired sera have IDs 1 and 15, 7 and 17, 8 and 14, 11 and 19, and 12 and 20.

<sup>†</sup>The data for USA-WA1/2020 and B.1.617.1 are from two independent experiments. The results for other variants are from one experiment each. For each independent experiment, the individual PRNT<sub>50</sub> value is the geometric mean of duplicate plaque assay results; no differences were observed between the duplicate assays.

<sup>‡</sup>The serum donors were white, except for donor 10, who was Asian. All donors were of non-Latino/Latina ethnicity.

<sup>§</sup>Geometric mean neutralizing titres.

<sup>||</sup>95% confidence interval (95% CI) for the geometric mean neutralizing titres.

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No sample size calculation was performed. Sample size was chosen based on previous experience and availability, 20 samples were collected from BNT162b2 vaccinees participating in the phase 1 portion of the ongoing phase 1/2/3 clinical trial (ClinicalTrials.gov identifier: NCT04368728). Those 20 samples had been tested as neutralizing positive against WT SARS-CoV-2 using the method according to the reference (Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020.).
Data exclusions	No data was excluded in the study.
Replication	The experiments were performed twice with 20 different samples. The averaged results from the duplication were reported in this study. All attempts at replication were successful.
Randomization	No randomization was performed. All samples were analyzed for the neutralizing activities against WT SARS-CoV-2 and variants in the same experimental settings.
Blinding	Patient information was blinded in the study. Those 20 samples had been tested as neutralizing positive against WT SARS-CoV-2 using the method according to the reference (Walsh EE, Frenck RW, Jr., Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med 2020.). The investigators were not blinded to the allocation during the experiments or to the outcome assessment. Blinding is not necessary because the results are quantitative and did not require subjective judgment or interpretation. Blinding is not typically used in the field.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	Vero E6 cells (ATCC® CRL-1586) were obtained from ATCC
Authentication	ATCC have comprehensively performed authentication on cell lines through STR profiling.
Mycoplasma contamination	All cell lines were tested negative for mycoplasma.
Commonly misidentified lines (See <a href="#">ICLAC</a> register)	No commonly misidentified cell lines were used in the study.